Caption Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.67M Buy
+100,000
New +$4.74M 0.02% 622
2025
Q3
Sell
-80,000
Closed -$5.52M 1938
2025
Q2
$5.52M Buy
+80,000
New +$5.44M 0.06% 377
2025
Q1
Sell
-185,000
Closed -$15.9M 1881
2024
Q4
$15.9M Buy
185,000
+120,300
+186% +$13M 0.15% 106
2024
Q3
$7.7M Buy
+64,700
New +$8.63M 0.12% 196
2024
Q1
Sell
-170,000
Closed -$17.6M 1543
2023
Q4
$17.6M Buy
+170,000
New +$16.8M 0.24% 101
2023
Q3
Sell
-200,400
Closed -$16.2M 1445
2023
Q2
$16.2M Buy
+200,400
New +$16.4M 0.29% 77

Other funds holding NVO

Caption Management's NVO Position: Q1 2026 in Review

Caption Management reduced its Novo Nordisk (NVO) stake by 24% in Q1 2026, selling an estimated $927K and leaving 60,600 shares worth $2.23M. The position accounts for 0.01% of the portfolio, ranked #794.

Caption Management first reported a position in NVO in Q3 2018 and has held it in 8 quarters since. The position peaked at $8.75M in Q4 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Caption Management held 60,600 shares of Novo Nordisk worth $2.23M as of Q1 2026.
  • Caption Management sold 19,571 Novo Nordisk shares in Q1 2026, an estimated $927K.
  • Novo Nordisk made up 0.01% of Caption Management's portfolio in Q1 2026, its #794 holding.
  • Caption Management first reported a position in Novo Nordisk in Q3 2018 and has held it in 8 quarters since.
  • Caption Management's Novo Nordisk position peaked at $8.75M in Q4 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.